메뉴 건너뛰기




Volumn 16, Issue 2, 2018, Pages 157-165

Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; ANTINEOPLASTIC AGENT;

EID: 85042364937     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-018-0377-7     Document Type: Article
Times cited : (27)

References (33)
  • 2
    • 77954888008 scopus 로고    scopus 로고
    • A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
    • PID: 19639352
    • Persson U, Willis M, Odegaard K. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden. Eur J Health Econ. 2010;11(2):195–203.
    • (2010) Eur J Health Econ. , vol.11 , Issue.2 , pp. 195-203
    • Persson, U.1    Willis, M.2    Odegaard, K.3
  • 4
    • 84944516806 scopus 로고    scopus 로고
    • reimbursement decisions for pharmaceuticals in sweden: the impact of disease severity and cost effectiveness
    • PID: 26093889
    • Svensson M, Nilsson FO, Arnberg K. reimbursement decisions for pharmaceuticals in sweden: the impact of disease severity and cost effectiveness. PharmacoEconomics. 2015;33(11):1229–36.
    • (2015) PharmacoEconomics. , vol.33 , Issue.11 , pp. 1229-1236
    • Svensson, M.1    Nilsson, F.O.2    Arnberg, K.3
  • 5
    • 85027379799 scopus 로고    scopus 로고
    • Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
    • PID: 28803265
    • Olofsson S, Gerdtham UG, Hultkrantz L, Persson U. Measuring the end-of-life premium in cancer using individual ex ante willingness to pay. Eur J Health Econ. 2017. https://doi.org/10.1007/s10198-017-0922-6.
    • (2017) Eur J Health Econ
    • Olofsson, S.1    Gerdtham, U.G.2    Hultkrantz, L.3    Persson, U.4
  • 6
    • 85044631979 scopus 로고    scopus 로고
    • [cited 2017 March 3rd]; Available from
    • NT-Council. Recommendations by the NT-council [Rekommendationer av NT-rådet]. 2017 [cited 2017 March 3rd]; Available from: http://www.janusinfo.se/Nationellt-inforande-av-nya-lakemedel/Nationellt-inforande-av-nya-lakemedel/Rekommendationer1/.
    • (2017) Recommendations by the NT-council [Rekommendationer av NT-rådet]
  • 7
    • 82555173357 scopus 로고    scopus 로고
    • National Guidelines for the Treatment of Breast, Prostate and Colorectal Cancers
    • Socialstyrelsen (The National Board of Health and Welfare). National Guidelines for the Treatment of Breast, Prostate and Colorectal Cancers; 2014.
    • (2014) The National Board of Health and Welfare
  • 8
    • 85010254179 scopus 로고    scopus 로고
    • Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
    • COI: 1:CAS:528:DC%2BC2sXktVKku7g%3D, PID: 27742709
    • Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128(24):2757–64.
    • (2016) Blood. , vol.128 , Issue.24 , pp. 2757-2764
    • Rajkumar, S.V.1    Harousseau, J.L.2
  • 12
    • 85044652088 scopus 로고    scopus 로고
    • [Underlag för beslut i landstingen; tilläggsanalys Kyprolis (karfilzomib)]. [Diarienummer: 2018/2016]
    • TLV. [Underlag för beslut i landstingen; tilläggsanalys Kyprolis (karfilzomib)]. [Diarienummer: 2018/2016]. 2017.
    • (2017)
  • 14
    • 84920846416 scopus 로고    scopus 로고
    • Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure
    • PID: 25595244
    • Navarria A, Drago V, Gozzo L, Longo L, Mansueto S, Pignataro G, et al. Do the current performance-based schemes in Italy really work? “Success fee”: a novel measure for cost-containment of drug expenditure. Value Health. 2015;18(1):131–6.
    • (2015) Value Health. , vol.18 , Issue.1 , pp. 131-136
    • Navarria, A.1    Drago, V.2    Gozzo, L.3    Longo, L.4    Mansueto, S.5    Pignataro, G.6
  • 15
    • 85027282325 scopus 로고    scopus 로고
    • Express Scripts leads indication-specific pricing with launch of OCV program
    • cited 2018 February 21st Available from
    • Kelly L. Express Scripts leads indication-specific pricing with launch of OCV program. Health Business Daily. 2016 [cited 2018 February 21st]; Available from: https://aishealth.com/archive/ndbn020516-02.
    • (2016) Health Business Daily
    • Kelly, L.1
  • 16
    • 84867287477 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs
    • PID: 22946789
    • Grima DT, Bernard LM, Dunn ES, McFarlane PA, Mendelssohn DC. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. PharmacoEconomics. 2012;30(11):981–9.
    • (2012) PharmacoEconomics. , vol.30 , Issue.11 , pp. 981-989
    • Grima, D.T.1    Bernard, L.M.2    Dunn, E.S.3    McFarlane, P.A.4    Mendelssohn, D.C.5
  • 17
    • 84877988784 scopus 로고    scopus 로고
    • Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al
    • PID: 23595557, (discussion 75–76)
    • van Baal P, Meltzer D, Brouwer W. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al. PharmacoEconomics. 2013;31(5):369–73 (discussion 75–76).
    • (2013) PharmacoEconomics. , vol.31 , Issue.5 , pp. 369-373
    • van Baal, P.1    Meltzer, D.2    Brouwer, W.3
  • 18
    • 84958125397 scopus 로고    scopus 로고
    • The end of the international reference pricing system?
    • PID: 26112982
    • Persson U, Jonsson B. The end of the international reference pricing system? Appl Health Econ Health Policy. 2016;14(1):1–8.
    • (2016) Appl Health Econ Health Policy. , vol.14 , Issue.1 , pp. 1-8
    • Persson, U.1    Jonsson, B.2
  • 19
    • 70350770990 scopus 로고    scopus 로고
    • The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
    • PID: 19624617
    • Garrison LP Jr, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. 2009;12(8):1118–23.
    • (2009) Value Health. , vol.12 , Issue.8 , pp. 1118-1123
    • Garrison, L.P.1    Veenstra, D.L.2
  • 20
    • 84908150068 scopus 로고    scopus 로고
    • Indication-specific pricing for cancer drugs
    • COI: 1:CAS:528:DC%2BC2cXitVSms7fN, PID: 25279433
    • Bach PB. Indication-specific pricing for cancer drugs. JAMA. 2014;312(16):1629–30.
    • (2014) JAMA. , vol.312 , Issue.16 , pp. 1629-1630
    • Bach, P.B.1
  • 22
    • 70350771916 scopus 로고    scopus 로고
    • Dynamic cost-effectiveness: A more efficient reimbursement criterion
    • Lundin D, Ramsberg J. Dynamic cost-effectiveness: a more efficient reimbursement criterion. In: Forum for Health Economics & Policy, vol 11, no 2. 2008.
    • (2008) Forum for Health Economics & Policy , vol.11 , Issue.2
    • Lundin, D.1    Ramsberg, J.2
  • 23
    • 85044622644 scopus 로고    scopus 로고
    • drugabacus.org. [cited 2017 March 3rd]; Available from
    • Bach PB. drugabacus.org. [cited 2017 March 3rd]; Available from: http://www.drugabacus.org/.
    • Bach, P.B.1
  • 26
    • 84855711056 scopus 로고    scopus 로고
    • Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement
    • PID: 22147861
    • Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011;30(12):2329–37.
    • (2011) Health Aff (Millwood). , vol.30 , Issue.12 , pp. 2329-2337
    • Neumann, P.J.1    Chambers, J.D.2    Simon, F.3    Meckley, L.M.4
  • 27
    • 77953704571 scopus 로고    scopus 로고
    • Multiple sclerosis risk sharing scheme: a costly failure
    • PID: 20522654
    • Raftery J. Multiple sclerosis risk sharing scheme: a costly failure. BMJ. 2010;340:c1672.
    • (2010) BMJ. , vol.340 , pp. c1672
    • Raftery, J.1
  • 28
    • 84901661562 scopus 로고    scopus 로고
    • Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers
    • PID: 24664994
    • Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP Jr. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy. 2014;12(3):231–8.
    • (2014) Appl Health Econ Health Policy. , vol.12 , Issue.3 , pp. 231-238
    • Carlson, J.J.1    Gries, K.S.2    Yeung, K.3    Sullivan, S.D.4    Garrison, L.P.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.